Zhitong Finance App News, Tianyi Healthcare (301097.SZ) announced that the company held the 3rd 14th board meeting on May 31, 2024 to review and pass the “Proposal on Joint Investment and Related Transactions with Related Parties” and agreed to increase the capital to Ningbo Tianhuiyi Enterprise Management Co., Ltd. (“Ningbo Tianhuiyi” or “SPV B” for short) by RMB 60 million. After the capital increase is completed, Tianyi Medical will hold 20.87% of Ningbo Tianhuiyi's shares.

TYHC International PTE, a wholly-owned subsidiary of Ningbo Tianhuiyi in Singapore. LTD (“Buyer”) signed a formal agreement with Nikkiso Co., Ltd. (“NKS” or “Seller”) on May 30, 2024 in Hanover, Germany, to acquire the CRRT business (“target business”) held by NKS in cash. The consideration for this transaction is estimated at 43.54 million euros. The target business specifically includes: (1) 100% of Nikkiso Europe GmbH (“NEG”) and 100% of Nikkiso Critical Care Medical Supply (Shanghai) Co., Ltd (“NMS”) held by NKS; (2) the subject matter held by NKS subsidiary Nikkiso Medical Thailand Co., Ltd. (“NMT”) Business-related assets; (3) CRRT business-related intellectual property held by NKS. Tianyi Medical plans to increase its capital to Ningbo Tianhuiyi by RMB 60 million. Ningbo Tianhuiyi's controlling shareholder is Ningbo Tianrunyi Management Consulting Partnership (Limited Partnership) (“Ningbo Tianrunyi” or “SPV A” for short), and Ningbo Tianrunyi was jointly invested and established by Tianyi Medical Holdings shareholders and actual controllers Wu Zhimin and Wu Bin, so this investment forms a related transaction. The current joint investment between the company and related parties will not have a significant impact on the company's financial situation and operating results in the short term. In the future, after integrating and standardizing the operation of the target business, the company will take the opportunity to choose whether to integrate into the listed company system.